Comparison of the efficiency of intravitreal dexamethasone implant and ranibizumab in the treatment of macular edema secondary to branch retinal vein occlusion: 6 Months results Retina ven dal tikanikliǧina baǧli makula ödemi tedavisinde intravitreal deksametazon implant ve ranibizumab etkinliǧinin karşilaştirilmasi: 6 Aylik sonuçlar


Türkseven Kumral E., Yenerel N. M., Şengül E. A., Imamoǧlu S., ERÇALIK N. Y., Sevim M. Ş., ...Daha Fazla

Retina-Vitreus, cilt.26, sa.2, ss.127-132, 2017 (Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 2
  • Basım Tarihi: 2017
  • Dergi Adı: Retina-Vitreus
  • Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.127-132
  • Anahtar Kelimeler: Branch retinal vein occlusion, Dexamethasone implant, Macular edema, Ranibizumab
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Purpose: To compare the efficiency of intravitreal dexamethasone implant and ranibizumab in the treatment of macular edema secondary to branch retinal vein occlusion at month 6. Methods: Sixty one eyes of 61 patients with macular edema secondary to branch retinal vein occlusion were evaluated retrospectively. Twenty-nine patients (group 1) received 0.7 mg single dose intravitreal dexamethasone implant and 32 patients (group 2) received 0.5 mg PRN ranibizumab injection. Best corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded at baseline and 6 th month of injection. Both groups were compared by means of efficieny. Results: Group 1 received single dose intravitreal dexamethasone implant and group 2 received mean 2.38±0.87 ranibizumab injections. Mean BCVA at baseline and month 6 was 1.0828±0.60419 and 0.7566±0.53714 logarithm of the minimum angle of resolution (logMAR) in group 1; 0.9891±0.50477 and 0.5781±0.41241 logMAR in group 2, respectively. Mean CMT at baseline and month 6 was 516.48±145.890 μm and 428.69±148.497 μm in group 1; 535.78±106.653 μm and 358.94±115.860 μm in group 2, respectively. There was an increase in BCVA and reduction in CMT in both groups at month 6 (p<0.05). But CMT in group 2 was significantly less than group1 (p<0.05). Conclusion: Both intravitreal dexamethasone implant and ranibizumab injection efficacy was found to be similar in the treatment of macular edema secondary to branch retinal vein occlusion. However, at month 6, ranibizumab appeared to have a greater effect on central macular thickness reduction compared to intravitreal dexamethasone implant.